Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 177Neoplasm Metastasis 19Breast Neoplasms 19Prostatic Neoplasms, Castration-Resistant 17Neoplasms 17Metastatic Castration Resistant Prostate Cancer 8Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Triple Negative Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Castration-resistant Prostate Cancer 4Carcinoma, Hepatocellular 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Prostate Adenocarcinoma 3Ovarian Neoplasms 3Carcinoma, Renal Cell 3mCRPC 2Uterine Cervical Neoplasms 2Recurrence 2Prostatic Diseases 2Metastatic Hormone Sensitive Prostate Cancer 2

Interventions

enzalutamide 1Warfarin 1Pioglitazone 1Omeprazole 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pharmacokinetics of MDV3100 × enzalutamide × Clear all
NCT01911728 2017-06-26

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Astellas Pharma Inc

Phase 1 Completed
14 enrolled
Genitourinary

Pharmacokinetics of MDV3100

Data powered by HemOnc (CC BY 4.0) Colophon âš¡